INS and type 2 diabetes mellitus: This trial aimed to evaluate the glucose control measured with CGM in participants with T2DM, based on the hypothesis that participants given PEG-Loxe would spend more time in TIR (3.9–10.0 mmol/L) than participants were given insulin glargine after 24 weeks of treatment.